Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: 10.63%

Jiangsu Hengrui Medicine Co., Ltd. Return on Equity (ROE) is 10.63% for the year ending December 31, 2023, a 2.95% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Jiangsu Hengrui Medicine Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was 10.33%, a -20.20% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was 12.94%, a -37.61% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was 20.75%, a -3.53% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 21.51%, a 4.35% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years